Aureka Biotechnologies is a technology company.
Aureka Biotechnologies has raised $23.0M across 1 funding round.
Aureka Biotechnologies has raised $23.0M in total across 1 funding round.
Aureka Biotechnologies is a biotech startup founded in 2023 that builds an AI-powered drug discovery platform focused on immunotherapies and protein therapeutics.[1][2][4] It serves the pharmaceutical industry by accelerating therapeutic design for complex targets, solving inefficiencies in traditional drug development like high costs and long timelines through rapid "design-build-test-learn" cycles powered by digital biology and machine learning.[1][2][3] The company, headquartered in Laguna Hills, California, has raised Seed VC funding from investors including K2VC, Niuerli Capital, and BioTools Innovator, positioning it as an early-stage player in AI-driven biotech with momentum in generative AI and drug discovery expert collections.[1]
Aureka Biotechnologies emerged in 2023 from a group of entrepreneurs and innovators frustrated with the pharma industry's inefficiencies, aiming to digitalize and democratize therapeutic discovery.[1][4] Led by CEO Weian Zhao, the founder-led team brings expertise in high-throughput synthetic biology, single-cell technologies, data science, computational biology, and deep learning, enabling them to tackle longstanding challenges in drug development.[3][4] Early traction includes Seed VC funding and inclusion in CB Insights expert collections for generative AI, AI in drug discovery, and artificial intelligence, marking pivotal validation in a competitive field.[1]
Aureka rides the explosive growth of AI in drug discovery, a trend where platforms and engines leverage generative AI to overhaul therapeutic development amid a pharma crisis of rising costs and stagnant innovation.[1][3] Timing is ideal as machine learning matures for protein design and single-cell analysis, fueled by market forces like urgent demand for novel immunotherapies and investor interest in biotech efficiency—evidenced by its Seed funding and expert collection placements.[1][2] By digitalizing design at scale, Aureka influences the ecosystem, potentially lowering barriers for new treatments and inspiring decentralized discovery models that benefit startups, pharmas, and patients.[4]
Aureka is poised to scale its platform toward Series A funding and initial therapeutic candidates, capitalizing on AI-biotech convergence to outpace rivals in immunotherapy speed.[1][2] Trends like advanced generative AI models and synthetic biology integration will shape its path, potentially enabling breakthroughs in hard-to-drug targets amid favorable VC momentum in the sector.[1][3] Its influence could evolve from niche innovator to ecosystem shaper, democratizing pharma as it proves clinical traction—reinforcing its mission to defeat disease through accessible, efficient discovery.[4]
Aureka Biotechnologies has raised $23.0M in total across 1 funding round.
Aureka Biotechnologies's investors include 5Y Capital, Kevin, Qiming Venture Partners.
Aureka Biotechnologies has raised $23.0M across 1 funding round. Most recently, it raised $23.0M Series A in September 2025.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Sep 1, 2025 | $23.0M Series A | 5Y Capital, Kevin, Qiming Venture Partners |